Stabilising procurement through multiple raw material suppliers and contract manufacturers
First written in FY2020. 7 of 8 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2018: 2 of 6 companies on the "Worse" side.
11 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period under review, there were no significant changes in the matters described in this interim report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
原料調達先・製造委託先の複数化に関する調達リスクについて、重要な変更はないと扱っている。 - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
原料調達先・製造委託先の複数化に関する調達リスクについて、重要な変更はないと扱っている。 - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
原料調達先・製造委託先の複数化に関する調達リスクについて、重要な変更はないと扱っている。 - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
原料調達先・製造委託先の複数化に関する調達リスクについて、重要な変更はないと扱っている。 - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
原料調達先・製造委託先の複数化に関する調達リスクについて、重要な変更はないと扱っている。 - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
原料調達先・製造委託先の複数化に関する調達リスクについて、重要な変更はないと扱っている。 - FY2021RestatedAnnual report
「当社グループでは、原料調達先や製造委託先の複数化を進めておりますが、相手先国での法規制の強化や取引先での操業事故などにより調達に制約を受けた場合、調達コストの上昇、生産の遅延や休止などを引き起こし、当社グループの業績に影響を及ぼす可能性があります。」
農薬原料・製造委託先の特定国集中を認識し、調達先・委託先の複数化を進める対策を継続している。 - FY2020First statedAnnual report
「当社グループでは、原料調達先や製造委託先の複数化を進めておりますが、相手先国での法規制の強化や取引先での操業事故などにより調達に制約を受けた場合、調達コストの上昇、生産の遅延や休止などを引き起こし、当社グループの業績に影響を及ぼす可能性があります。」
特定国に集中する傾向がある農薬原料調達・製造委託について、調達先・委託先の複数化を進める対策を記載している。